Particle.news
Download on the App Store
40 ARTICLES
·
last wk.

Novo Nordisk to Cut 9,000 Jobs in Major Overhaul as GLP‑1 Rivalry Intensifies

The overhaul redirects savings to GLP‑1 R&D, aiming to speed decisions in a tougher, consumer‑driven market.

Image
Image
An employee works on the production line at the Novo Nordisk factory in Hilleroed on September 26, 2023. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark, aiming to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. On June 12, 2023, the company announced plans to invest 15.9 billion Danish kroner to expand an existing Active Pharmaceutical Ingredient (API) production facility in the country. (Photo by Sergei GAPON / AFP) (Photo by SERGEI GAPON/AFP via Getty Images)

Overview

  • The reductions equal about 11% of the 78,400-person workforce, with roughly 5,000 roles eliminated in Denmark.
  • Novo targets about 8 billion Danish kroner in annual savings by 2026 and expects roughly 1 billion kroner of savings in the fourth quarter of 2025.
  • The company will book about 9 billion kroner in one‑off restructuring costs this year and cut its 2025 operating profit growth outlook to 4%–10%.
  • Implementation begins immediately under new CEO Mike Doustdar, who is reallocating resources to obesity and diabetes research and to capacity expansion.
  • Management cites intensified competition from Eli Lilly and continued use of compounded copycats, and news outlets reported this as Denmark’s largest layoff.